SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly results and outlook are driving attention, with traders focused on rapid AI-compute growth, a return to profitability and plans for heavy infrastructure spending. Bulls see the results as evidence of an expanding AI business, while skeptics question the valuation, cash demands and potential share-unlock pressure; preliminary Tesla merger discussions add another speculative theme.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix shares are under pressure after its quarterly profit beat expectations, but a softer fourth-quarter outlook and slowing revenue growth overshadowed the results; the company also lowered its advertising revenue forecast. Bears see growth and ad execution as key concerns, while bulls argue the selloff overstates the risk given the profitable quarter and share buybacks.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reported Chinese orders for Nvidias export-compliant GPUs are renewing discussion of strong AI-chip demand, though traders are frustrated that the news has not translated into a stronger share-price response. The debate also reflects optimism about continued AI infrastructure spending after SpaceX and Super Micro updates, balanced by worries about valuations, financing, and whether that spending will generate returns.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary fiscal Q1 update sharply raised its sales outlook and projected improved gross margins, citing stronger AI-platform demand. Bulls welcomed the upside surprise and speculated about short covering, while skeptics questioned whether the gains and improved margins would hold.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys upcoming Q3 earnings are the main focus, with traders debating whether results and guidance can justify its premium valuation after a sharp, volatile pullback. Bulls point to fuel-cell demand from AI data centers and recent power-project deals, while skeptics warn that expectations are high and the broader AI selloff could keep shares under pressure.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS shares sharp rebound has traders focused on the anticipated 80th-event trigger and final analysis of its Phase 3 REGAL AML trial, with some also speculating about a buyout. The event count and trial results remain unconfirmed; bullish expectations of a major catalyst are countered by skepticism that the move is trading momentum without new data.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Traders are focused on potential DefenCath reimbursement upside after the HHS kidney-care plan highlighted barriers to financing dialysis innovation, which they see as support for CorMedixs request for a separate infection-prevention payment category. CMS action remains uncertain, and the discussion also weighs DefenCaths adoption and pricing against competition; REZZAYOs FDA priority review is another cited growth catalyst.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is being swept up in a semiconductor selloff as traders question the returns and financing behind AI infrastructure spending; Hock Tans casino remarks have added to skepticism. The community is split between dip-buyers pointing to continuing AI-chip demand and bearish traders focused on AVGOs weak performance, credit concerns, and the risk of further declines.

Tema ETF Trust - Tema Space Innovators ETF

Tema Space Innovators ETF

NASA is drawing attention after sliding to a 52-week low amid persistent weakness in the space sector and disappointment with the ETFs performance after the space-trade hype faded. Traders are split between calling it oversold and averaging down versus rotating into individual space names such as Rocket Lab, AST SpaceMobile, or SpaceX.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Traders are focused on Seas reported plans for a Monee fintech listing and a new AI cloud business, with the announcements coinciding with a sharp selloff. The community is split between seeing the moves as potential value creation and worrying about uncertainty, spending, and Shopee competition; some also view the decline as an oversold buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 75.6% in Vaxcyte (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Vaxcyte Prices Offerings Of Stock, Warrants, Convertible Notes To Raise Approx. $1 Bln

(RTTNews) - Vaxcyte, Inc. (PCVX), a clinical-stage vaccine innovation company, announced late Tuesday the pricing of public offerings of common stock, pre-funded warrants and convertible senior notes for total proceeds of approximately $1.0 billion...

Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety

Vaccine stocks are trending on Tuesday.

Shares of Moderna Inc. (NASDAQ:MRNA), Vaxcyte Inc. (NASDAQ:PCVX) and Novavax Inc. (NASDAQ:NVAX) are moving in the after-hours session on Monday.

Moderna rose 0.17% toread more...

NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test

Equity

Vaxcyte said earlier on Monday that its experimental pneumonia vaccine, VAX-31, met the main goals of a late-stage study in adults 50 and older.


PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case

In the OPUS-1 study, Vaxcyte’s VAX-31 matched or beat immune responses from Pfizer’s Prevnar 20 and Merck’s Capvaxive on most strains those vaccines cover. 

Stocks making the biggest moves midday: Microsoft, SpaceX, Vaxcyte, Banco Bradesco, DraftKings & more

Here are some of the companies making headlines in midday trading...

RXO, Vaxcyte, PTC And Other Big Stocks Moving Higher On Monday

U.S. stocks mixed as Dow falls 250+ points; RXO surges 23% on $5.8B C.H. Robinson deal, while Vaxcyte and PTC post major gains.read more...

Vaxcyte Stock Hits New 52-Week High - Here's Why

Vaxcyte announced positive Phase 3 OPUS-1 trial results for its VAX-31 vaccine candidate, setting the stage for an FDA BLA filing.read more...

Vaxcyte’s VAX-31 Clears Major Phase 3 Hurdle

Vaxcyte (NASDAQ:PCVX) delivered the kind of pivotal clinical readout that can fundamentally reshape a biotech investment story: its 31-valent pneumococcal vaccine candidate, VAX-31, met all prespecified primary endpoints in the pivotal OPUS-1 Phase 3 trial.

Vaxcyte's VAX-31 Meets Key Phase 3 Goals Against Prevnar 20 And Capvaxive; Stock Up

(RTTNews) - Monay, Vacyte (PCVX) reported positive topline results from its pivotal Phase 3 OPUS-1 trial, with VAX-31 meeting all prespecificed primary endpoints in adults...

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Vaxcyte Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Moderna shares rose about 7% while BioNTech edged 1% higher.</li><li>Reports of a suspected plague outbreak in Russia also triggered vaccine sectorwide optimism.&nbsp;</li><li>Novavax relies on partnerships to sell its vaccines.</li></ul><p>Shares of Novavax Inc. (NVAX) jumped 20% on Monday, clocking its best session since January, as a rival’s strong trial result lifted vaccine stocks amid speculation about a plague outbreak in Russia.</p><p>Moderna shares rose about 7%, a move also tied to its pending addition to the Nasdaq-100, while BioNTech edged 1% higher after Vaxcyte announced positive trial results for its pneumonia vaccine. Separately, reports of a suspected plague outbreak in Russia also triggered sectorwide optimism.</p><h2 class="st-heading-2">PCVX’s Trial Sets The Tone</h2><p>Vaxcyte said earlier on Monday that its experimental pneumonia vaccine, VAX-31, met the main goals of a late-stage study in adults 50 and older.</p><p>The shot is designed to cover 31 strains of the bacteria that cause pneumococcal disease, which can lead to pneumonia, meningitis and bloodstream infections. In the study, immune responses were at least comparable to Pfizer’s Prevnar 20 and Merck’s Capvaxive on the strains those vaccines already cover, and stronger on three strains unique to VAX-31. Vaxcyte said the safety profile was consistent across the age groups tested.</p><p>Vaxcyte <a href="https://stocktwits.com/news-articles/markets/equity/pcvx-stock-hits-fresh-52-week-high-on-late-stage-win-in-adult-pneumonia-vaccine-race-jefferies-says-it-hit-blue-sky-case/cZDq3huRBjF">shares rose</a> 31% in regular trading and revived interest in vaccine makers.</p><h2 class="st-heading-2">Why Novavax Drew A Bid</h2><p>Novavax’s own story is about partnerships. In late August, the company said partners Sanofi and Takeda had won approval for an updated version of its protein-based COVID-19 vaccine, Nuvaxovid, in the United States, the European Union and Japan ahead of the 2026–2027 season. In the U.S., the shot is cleared for people 65 and older and for those 12 to 64 with a condition that raises the risk of severe illness.</p><p>Sanofi holds the commercial rights in most markets and is carrying the vaccine into the fall season in the United States, the United Kingdom, Germany and Canada. Novavax no longer sells it itself. It collects royalties on partner sales and is still due a $75 million manufacturing technology-transfer payment, which it has said it expects in the fourth quarter.</p><h2 class="st-heading-2">Plague Outbreak Concerns</h2><p>Over the weekend, reports circulated that a Russian lab worker has died from a possible case of pneumonic plague while working at the Research Anti-Plague Institute of Siberia. The reports are unconfirmed.</p><p>According to a report from Axios, President Trump said on Monday that the U.S. will help Russia in case of a pneumonic plague outbreak. Axios also reported that the White House is monitoring the outbreak. Novavax, however, has no plague vaccine.</p><h2 class="st-heading-2">How Did NVAX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around <a class="mention" data-mention="$NVAX" data-symbol-id="NVAX" href="https://stocktwits.com/symbol/NVAX" target="_blank">NVAX stock</a> stayed within the bullish territory at the time of writing, while message volume rose from normal to high levels.</p><p>A Stocktwits user noted that NVAX rallied during the Covid-19 pandemic, suggesting a similar rally could follow a plague outbreak.</p><p><stembedurl>https://stocktwits.com/Johnmtnb2018/message/665794013</stembedurl></p><p>Another voiced optimism for more big pharmaceutical companies partnering with Novavax for its Matrix-M technology.</p><p><stembedurl>https://stocktwits.com/Flowdollas777/message/665793666</stembedurl></p><p>NVAX stock has gained 87% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lcid-stock-stays-flat-after-hours-on-q3-sales-dip-while-tsla-rivn-beat-estimates/cZDqXBjRBjs">LCID Stock Stays Flat After-Hours On Q3 Sales Dip While TSLA, RIVN Beat Estimates</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Novavax continues to suffer from weak demand for its COVID-19 shots.

Vaxcyte said earlier on Monday that its experimental pneumonia vaccine, VAX-31, met the main goals of a late-stage study in adults 50 and older.

Moderna Inc

Novavax Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$66.23
Prev Close	$63.68
Open	$63.80
Dividend Yield	0.00%
50-Day Moving Average	$61.35
Beta	0.82
Avg. Volume	1.41M
PE Ratio	-8.59

52-Week High	$90.75
52-Week Low	$39.87
Market Capitalization	$10.02B
EPS (Annual)	-$5.63
Price to Book	3.48
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

PCVX Fundamentals